Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia

被引：0
|
作者：
Guro F Giskeødegård
Ailin Falkmo Hansen
Helena Bertilsson
Susana Villa Gonzalez
Kåre Andre Kristiansen
Per Bruheim
Svein A Mjøs
Anders Angelsen
Tone Frost Bathen
May-Britt Tessem
机构：
[1] Norwegian University of Science and Technology (NTNU),Department of Circulation and Medical Imaging
[2] Trondheim 7491,Department of Cancer Research and Molecular Medicine
[3] Norway,Department of Urology
[4] St Olav University Hospital,Department of Chemistry
[5] Norwegian University of Science and Technology (NTNU),Department of Biotechnology
[6] NTNU,Department of Chemistry
[7] NTNU,undefined
[8] NTNU,undefined
[9] University of Bergen,undefined
来源：
British Journal of Cancer | 2015年 / 113卷
关键词：
metabolomics; serum; plasma; prostate cancer; MRS; MS; GC; acylcarnitines; glycerophospholipids; arginine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1712 / 1719
页数：7
相关论文
共 50 条
  • [41] PSA-based parameters and their diagnostic performances in patients with prostate cancer and benign prostatic hyperplasia
    Kocer, Derya
    Karakukcu, Cigdem
    Karaman, Hatice
    Tasdemir, Arzu
    Ergul, Mehmet Ali
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2013, 38 (01): : 37 - 42
  • [42] The use of beta-sitosterol for the treatment of prostate cancer and benign prostatic hyperplasia
    Macoska, Jill A.
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2023, 11 (06): : 467 - 480
  • [43] Oxidative Stress and Body Composition in Prostate Cancer and Benign Prostatic Hyperplasia Patients
    Cimino, Sebastiano
    Favilla, Vincenzo
    Russo, Giorgio Ivan
    Galvano, Fabio
    Li Volti, Giovanni
    Barbagallo, Ignazio
    Giofre, Salvatore Vincenzo
    D'Orazio, Nicolantonio
    Di Rosa, Alessandro
    Madonia, Massimo
    Morgia, Giuseppe
    ANTICANCER RESEARCH, 2014, 34 (09) : 5051 - 5056
  • [44] Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence
    Pettaway, Curtis A.
    Lamerato, Lois E.
    Eaddy, Michael T.
    Edwards, Jessie K.
    Hogue, Susan L.
    Crane, Martin M.
    BJU INTERNATIONAL, 2011, 108 (08) : 1302 - 1308
  • [45] Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hyperplasia
    Wolff, JM
    Borchers, H
    Brehmer, B
    Brauers, A
    Jakse, G
    UROLOGIA INTERNATIONALIS, 1998, 60 (03) : 152 - 155
  • [46] The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation
    De Nunzio, Cosimo
    Kramer, Gero
    Marberger, Michael
    Montironi, Rodolfo
    Nelson, William
    Schroder, Fritz
    Sciarra, Alessandro
    Tubaro, Andrea
    EUROPEAN UROLOGY, 2011, 60 (01) : 106 - 117
  • [47] Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio
    Kaynar, Mehmet
    Yildirim, Mehmet Erol
    Gul, Murat
    Kilic, Ozcan
    Ceylan, Kadir
    Goktas, Serdar
    CANCER BIOMARKERS, 2015, 15 (03) : 317 - 323
  • [48] Cadmium Concentration and Metallothionein Expression in Prostate Cancer and Benign Prostatic Hyperplasia of Humans
    Lee, Jane-Dar
    Wu, Su-Mei
    Lu, Lieng-Yi
    Yang, Ya-Tang
    Jeng, Shaw-Yeu
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2009, 108 (07) : 554 - 559
  • [49] Potential Efficacy of Some African Plants in Benign Prostatic Hyperplasia and Prostate Cancer
    Russo, Giorgio I.
    Cimino, Sebastiano
    Salamone, Costanza
    Madonia, Massimo
    Favilla, Vincenzo
    Castelli, Tommaso
    Morgia, Giuseppe
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2013, 13 (11) : 1564 - 1571
  • [50] Serum interleukin-11 in patients with benign prostatic hyperplasia and prostate cancer
    Furuya Y.
    Nishio R.
    Junicho A.
    Nagakawa O.
    Fuse H.
    International Urology and Nephrology, 2005, 37 (1) : 69 - 71
12345